Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1731348/000156459022026894/tlry-10k_20220531.htm
August 2022
July 2022
July 2022
June 2022
June 2022
June 2022
April 2022
April 2022
April 2022
March 2022
Exhibit 99.1
|
|
PRESS RELEASE |
July 28, 2022 |
Tilray Brands, Inc. Reports Record Fiscal Year 2022 Results
FY2022 Net Revenue Grew 22% to $628 Million Compared to the Prior Year; On a Constant Currency Basis, Net Revenue Increased by 29%
Fourth Quarter Net Revenue Grew 8% to $153 Million Compared to the Prior Year Period; On a Constant Currency Basis, Net Revenue Increased by 14% to $163 Million
Company Expects to Generate $70-$80 Million of Adjusted EBITDA and be Free-Cash Flow Positive in Its Operating Business Units in FY2023
Foundation in Place for Profitable and Sustainable Growth
|
• |
Fourth Quarter International Cannabis Increased 205% from the Prior Year Q4; Tilray Medical Leads European Medical Cannabis Market with 20% Market Share in Germany |
|
• |
Delivered $85 Million in Cost Savings to Date, Exceeding Original Target on Accelerated Timeline; Company Now Expects to Deliver $100 Million by the End of FY2023 |
|
• |
Significantly Strengthened Balance Sheet, Reduced Debt, and Ended FY2022 with $416 Million in Cash |
|
• |
Tilray Brands Sets Stage for Next Evolution of Cannabis Following HEXO Transaction, which Positions the Company for Additional Growth Opportunities in Canada, Europe, and the U.S |
NEW YORK and LEAMINGTON, ONTARIO – July 28, 2022 – Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported financial results for the fourth quarter and full fiscal year ended May 31, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated, and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”).
Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer, stated, “Over the past year, we have accelerated the optimization of our operations and sharpened execution against our most profitable core business opportunities in medical, adult-use, wellness, and beverage-alcohol across Canada, Europe, and the U.S. At the same time, we accelerated our growth potential through tactical execution
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1731348/000156459022026894/tlry-10k_20220531.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Tilray, Inc..
Tilray, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
Due to this increased competition in the market, we maintained our market leadership for the year, but experienced a decline in market share to 11.7%, as reported by Hifyre data; and The decrease is also attributable to the decline in the Canadian dollar from the prior year ended May 31, 2021.
For the year ended May 31, 2022, adjusted EBITDA increased primarily from favorable effects of new lines of business, offset by the inclusion of legacy Tilray's cannabis business, while we work to achieve our synergies plan, as follows: The Company's adjusted EBITDA increased by $7.3 million from $40.8 in the prior year, to $48.0 million in the current year.
The decline was partially driven by the government lockdowns reinstated in Ontario to combat the Omicron variant, as well as vaccine passport requirements to shop in retail stores in Quebec, reducing consumer's accessibility to our products; We also experienced additional declines in average gross selling price due to increased price-based competition due to the high volume of new entrants in the market.
In addition, we are relentlessly focused on managing our cost of goods and expenses in order to maintain our strong financial position.
Significant estimates in the discounted...Read more
Please see "Reconciliation of Non-GAAP...Read more
The purchase price consisted of...Read more
In executing our integration plan,...Read more
The Company calculates adjusted EBITDA...Read more
We use certain non-GAAP measures...Read more
Transaction costs largely relate to...Read more
Actual inventory losses may differ...Read more
Distribution gross margin: Gross margin...Read more
While we believe we have...Read more
Adjusted EBITDA is a non-GAAP...Read more
The remaining increase was due...Read more
This was primarily related to...Read more
As a result, the prior...Read more
The company used a discount...Read more
The decrease in gross margin...Read more
Changes in the regulatory structure,...Read more
While we continue to execute...Read more
The decrease in distribution revenue...Read more
Wellness gross margin: Gross margin...Read more
A detailed discussion of our...Read more
Adjusted gross margin of 43%...Read more
Beverage alcohol gross margin: Gross...Read more
Adjusted gross margin of 58%...Read more
This resulted in a general...Read more
These measures, which may be...Read more
On a constant currency basis,...Read more
Total operating expenses for the...Read more
Other companies, including companies in...Read more
Building upon SweetWaters's strategic plan...Read more
Our overall strategy is to...Read more
In connection with the Tilray-Aphria...Read more
Revenue from Distribution operations for...Read more
Revenue for the year ending...Read more
Revenue is recognized when the...Read more
Overall, the gross margin and...Read more
We use the following operating...Read more
The sales and associated EBITDA...Read more
We continued efforts to close...Read more
This consumer model of purchasing...Read more
Sweetwater revenue increased in the...Read more
If neither of the conditions...Read more
We incurred impairment expense of...Read more
We believe that existing cash,...Read more
In order to ensure the...Read more
We believe that these initiatives,...Read more
For the year ended May...Read more
These policies and estimates are...Read more
In our international cannabis business,...Read more
As a result, we incur...Read more
The conversion price of the...Read more
We lease various facilities, under...Read more
Revenue from our Beverage Alcohol...Read more
Adjusted EBITDA excludes: Non-cash inventory...Read more
Further enhancing this increase, the...Read more
Insurance expenses increased by 43%...Read more
The Company is committed to...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Tilray, Inc. provided additional information to their SEC Filing as exhibits
Ticker: TLRY
CIK: 1731348
Form Type: 10-K Annual Report
Accession Number: 0001564590-22-026894
Submitted to the SEC: Thu Jul 28 2022 4:26:46 PM EST
Accepted by the SEC: Thu Jul 28 2022
Period: Tuesday, May 31, 2022
Industry: Medicinal Chemicals And Botanical Products